DrugDev Showcases Golden Number Global Identifier for Clinical Trial Personnel, Facilities; SaaS-based Site Activation Module at Clinical Innovation Congress 9-10 March
Cloud-based technologies based on years of proven best practices enable pharma sponsors and CROs to use secure single sign-on, make evidence-based decisions, and reduce clinical study startup time by at least 20%
LONDON, UK and KING OF PRUSSIA, PA – 7 March – DrugDev will demonstrate innovative clinical operations technologies aimed at promoting standardization, industry-wide collaboration, and a beautiful technology experience at the Clinical Innovations Congress in London, 9-10 March:
How One (Golden) Number Can Transform Clinical Trials, 9 March, 4:30pm – DrugDev’s Associate Director Bryan Dobson will discuss the impact of the DrugDev Golden Number – a unique identifier used to match and master Investigator and site information – on speeding site activation. With the DrugDev Golden Number individual pharma companies and CROs easily match and master data, and share data across collaborations like the Investigator Databank and TransCelerate. Join this session for an update on the Golden Number and how pharma is using it to improve the efficiency of clinical trials.
The DrugDev Site Activation Module, 9 March 5:10 pm – At the Congress Tech Showcase Kirsty Kwiatkowski, Director, SiteStart will demonstrate DrugDev’s new SaaS-based Site Activation Module, which will drastically reduce clinical trial startup time and ease the administrative burden on sites. The Site Activation Module is a cloud-based technology that is driven by a customizable workflow optimization engine that simplifies e-feasibility, contract and budget negotiations, and the collection and maintenance of essential site regulatory documents. Productivity and collaboration are increased with global transparency, real time dashboards, metrics and reporting and more to reduce startup time by at least 20%.
About the Presenters
Bryan Dobson, Associate Director, DrugDev – Bryan has direct line management of Research Associates at DrugDev, and is responsible for data management and curation of the DrugDev Golden Number. Prior to DrugDev Bryan was a Research Scientist in the Defence Technology Agency of the New Zealand Defence Force.
Kirsty Kwiatkowski, Director, SiteStart – Kirsty oversees SiteStart activities and the DrugDev Investigator Network. Kirsty is passionate about clinical research and the evolution of the clinical trials process and has many years of clinical and regulatory operations experience. Previously Kirsty managed clinical trials and teams of clinical trialists at Vernalis, Johnson & Johnson and Pharm-Olam, where she worked across all phases of clinical research and several therapeutic areas.
Read what top pharmaceutical industry publications say about the DrugDev Site Activation Module:
http://bit.ly/CINonSiteActivationModule
http://bit.ly/ACT-SiteActivationModule
Learn more about the Clinical Innovation Congress here: http://www.healthnetworkcommunications.com/conference/disruptive-innovation
About DrugDev
DrugDev, which has offices in London, UK; King of Prussia, PA; and Boston, MA, is an innovative technology company which provides cloud-based solutions to help sponsors, CROs and investigators do more clinical trials together. DrugDev’s unified platform optimizes site selection and activation, investigator payments and clinical operations efficiency. DrugDev also serves as the trusted third-party host of the revolutionary Investigator Databank collaboration and the TransCelerate Investigator Registry. Learn why 9 of the top 10 sponsors and 4 of the top 5 CROs trust on DrugDev technology to do more trials at drugdev.com.
Media Contact: Brenda Nashawaty, +1 617.688.3253, brenda@nashawaty.com